Association Between Hormone Receptors and HER-2/neu is Age-related

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2015 Sep 5

PMID 26339420

Citations 3

Authors

Bo Wang

Xiaoling Wang

Yinying Zou

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the association between hormone receptors and HER-2/neu in different age groups of women with breast cancers.

Methods: A total of 1036 women with breast cancers were recruited. All the patients were divided into nine groups. The expression of hormone receptors and HER-2/neu was studied by IHC, while FISH test was used to determine HER-2/neu status in cases scored IHC 2+. The association between hormone receptors and HER-2/neu in different age groups was evaluated using the χ(2) test. Multivariate analysis was used to find out the independent factors predicting HER-2/neu amplification. Significant findings: The expression of ER and PR was inversely correlated with HER-2/neu status in women aged >40 years. By multivariate analysis, as far as the overall groups were concerned, PR, lymph node status and tumor grade were independently associated with HER-2/neu; Considering the younger age group (≤ 40), the only predictor for HER-2/neu was the tumor grade; Considering the older age group (>40), tumor grade, PR status, tumor size and lymph node status were associated with HER-2/neu overexpression.

Conclusions: Our data suggest that the association between ER, PR and HER-2/neu is age-related. The negative relationship is only applied for women aged >40 years.

Citing Articles

Masculinization of Adult : A Case of Recapitulation of Protogyny in a Gonochorist?.

Tran N, Kwan T, Purser J, Patil J Biology (Basel). 2022; 11(5).

PMID: 35625423 PMC: 9138882. DOI: 10.3390/biology11050694.

Hormonal Receptors, Human Epidermal Growth Factor Receptor-2 and Triple Negative Immunohistochemical Typing in Women with Breast Cancer in Kampala, Uganda.

Mlole A, Yahaya J, Othieno E, Kalungi S, Okwi A Int J Womens Health. 2020; 12:1109-1123.

PMID: 33343201 PMC: 7745719. DOI: 10.2147/IJWH.S270082.

Evaluation of Immunohistochemistry-Equivocal (2+) HER2 Gene Status in Invasive Breast Cancer by Silver DNA in Situ Hybridization (SISH) and its Association with Clinicopathological Variables.

A Musa Z, J Qasim B, A K Al Shaikhly A Iran J Pathol. 2018; 12(1):9-19.

PMID: 29760748 PMC: 5938719.

References

Deshpande A, Jeffe D, Gnerlich J, Iqbal A, Thummalakunta A, Margenthaler J . Racial disparities in breast cancer survival: an analysis by age and stage. J Surg Res. 2008; 153(1):105-13. PMC: 3240670. DOI: 10.1016/j.jss.2008.05.020. View

Curado M . Breast cancer in the world: incidence and mortality. Salud Publica Mex. 2012; 53(5):372-84. View

Tiwari R, Borgen P, Wong G, Cordon-Cardo C, Osborne M . HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res. 1992; 12(2):419-25. View

Phipps A, Malone K, Porter P, Daling J, Li C . Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer. 2008; 113(7):1521-6. PMC: 2587413. DOI: 10.1002/cncr.23786. View

Wang Q, Li J, Zheng S, Li J, Pang Y, Huang R . Breast cancer stage at diagnosis and area-based socioeconomic status: a multicenter 10-year retrospective clinical epidemiological study in China. BMC Cancer. 2012; 12:122. PMC: 3338083. DOI: 10.1186/1471-2407-12-122. View

Love R, Duc N, Havighurst T, Mohsin S, Zhang Q, DeMets D . Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol. 2003; 21(3):453-7. DOI: 10.1200/JCO.2003.10.133. View

Gullick W, Love S, Wright C, Barnes D, Gusterson B, Harris A . c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer. 1991; 63(3):434-8. PMC: 1971853. DOI: 10.1038/bjc.1991.100. View

Zeillinger R, Kury F, Czerwenka K, Kubista E, Sliutz G, Knogler W . HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene. 1989; 4(1):109-14. View

Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R . Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000; 18(21):3651-64. DOI: 10.1200/JCO.2000.18.21.3651. View

10.

Lund M, Trivers K, Porter P, Coates R, Leyland-Jones B, Brawley O . Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat. 2008; 113(2):357-70. DOI: 10.1007/s10549-008-9926-3. View

11.

Kurian A, Fish K, Shema S, Clarke C . Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res. 2010; 12(6):R99. PMC: 3046442. DOI: 10.1186/bcr2780. View

12.

Schootman M, Jeff D, Gillanders W, Yan Y, Jenkins B, Aft R . Geographic clustering of adequate diagnostic follow-up after abnormal screening results for breast cancer among low-income women in Missouri. Ann Epidemiol. 2007; 17(9):704-12. DOI: 10.1016/j.annepidem.2007.03.017. View

13.

Vaidyanathan K, Kumar P, Reddy C, Deshmane V, Somasundaram K, Mukherjee G . ErbB-2 expression and its association with other biological parameters of breast cancer among Indian women. Indian J Cancer. 2010; 47(1):8-15. DOI: 10.4103/0019-509X.58852. View

14.

Rosenberg J, Chia Y, Plevritis S . The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the U.S. SEER database. Breast Cancer Res Treat. 2005; 89(1):47-54. DOI: 10.1007/s10549-004-1470-1. View

15.

Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z . Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003; 95(2):142-53. DOI: 10.1093/jnci/95.2.142. View

16.

Maynard P, Davies C, Blamey R, Elston C, Johnson J, Griffiths K . Relationship between oestrogen-receptor content and histological grade in human primary breast tumours. Br J Cancer. 1978; 38(6):745-8. PMC: 2009828. DOI: 10.1038/bjc.1978.282. View

17.

Russell K, Hung M . Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. Cancer Res. 1992; 52(23):6624-9. View

18.

Bauer K, Brown M, Cress R, Parise C, Caggiano V . Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007; 109(9):1721-8. DOI: 10.1002/cncr.22618. View

19.

Schootman M, Walker M, Jeffe D, Rohrer J, Baker E . Breast cancer screening and incidence in communities with a high proportion of uninsured. Am J Prev Med. 2007; 33(5):379-386. PMC: 2100034. DOI: 10.1016/j.amepre.2007.07.032. View

20.

Li C, Malone K, Daling J . Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev. 2002; 11(7):601-7. View